|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Vertebrate Primary Cilium in Development, Homeostasis, and Disease显示文摘 | Jantje M. Gerdes Erica E. Davis Nicholas Katsanis | 2009 | Cell2009，，1： | 1 |
| 2 | Synergistic Role of TRPV1 and TRPA1 in Pancreatic Pain and Inflammation显示文摘 | Erica S. Schwartz Julie A. Christianson Xiaowei Chen Jun–Ho La Brian M. Davis Kathryn M. Albers G.F. Gebhart | 2011 | Gastroenterology2011，，4： | 1 |
| 3 | Heart failure symptom burden,dietary intake,and inflammation:An integrative review of the literature显示文摘Heart failure(HF)is characterized by high symptom burden including,but not limited to fatigue,dyspnea,and edema.Up to 21.5%of HF patients experience significant depressive symptoms,much higher than 7.1%in adults without HF.Diet,metabolites,and other inflammatory mechanisms have gained notable attention in recent studies for contributions to symptoms in HF.Symptoms for black adults(B/As)with HF are often influenced by lifestyle factors,which may influence their higher mortality rates;few studies address these factors.Distinguishing the links between key elements with diet,inflammation,and symptoms may bring clarity for new dietary strategies in HF clinical care.The purpose of this integrative review is to examine the existing literature regarding relationships among physiologic pathways in HF along with physical and emotional symptoms in the context of inflammation,dietary intake,tumor necrosis factor‑alpha(TNF‑a),a biomarker of inflammation,and trimethylamine‑N‑Oxide(TMAO).Based on available evidence,inflammation may be a key link between physical symptoms,diet,depression,TMAO,and TNF‑a in persons with HF and warrants further examination to clarify pathological links to solidify evidence for better guidance with dietary modifications.The literature reviewed in this study demonstrates that more work is needed to examine dietary planning,social support,and differences between men and women in the B/A community.Results of this literature review call attention to the essential,personalized care needs related to symptom monitoring and dietary planning which is expected to decrease symptom burden in the HF population. | Erica DAVIS Sandra DUNBAR Melinda HIGGINS Kathryn WOOD Erin FERRANTI Alanna MORRIS Brittany BUTTS | 2023 | Journal of Integrative Nursing2023，5，2： | 0 |
| 4 | Real-world treatment attrition rates in advanced esophagogastric cancer显示文摘BACKGROUND Over the last decade,multiple agents have demonstrated efficacy for advanced esophagogastric cancer(EGC).Despite the availability of later lines of therapy,there remains limited real-world data about the treatment attrition rates between lines of therapy.AIM To characterize the use and attrition rates between lines of therapy for patients with advanced EGC.METHODS We identified patients who received at least one cycle of chemotherapy for advanced EGC between July 1,2017 and July 31,2018 across six regional centers in British Columbia(BC),Canada.Clinicopathologic,treatment,and outcomes data were extracted.RESULTS Of 245 patients who received at least one line of therapy,median age was 66 years(IQR 58.2-72.3)and 186(76%)were male,Eastern Cooperative Oncology Group(ECOG)performance status 0/1(80%),gastric vs GEJ(36%vs 64%).Histologies included adenocarcinoma(78%),squamous cell carcinoma(8%),and signet ring(14%),with 31%HER2 positive.72%presented with de novo disease,and 25%had received previous chemoradiation.There was a high level of treatment attrition,with patients receiving only one line of therapy n=122,50%),two lines n=83,34%),three lines n=34,14%),and four lines n=6,2%).Kaplan-Meier analysis demonstrated improved survival with increasing lines of therapy(median overall survival 7.7 vs 16.6 vs 22.8 vs 40.4 mo,P<0.05).On multivariable Cox regression,improved survival was associated with better baseline ECOG and increased lines of therapy(P<0.05).CONCLUSION The steep attrition rates between therapies highlight the unmet need for more efficacious early-line treatment options for patients with advanced EGC. | Erica S Tsang Howard J Lim Daniel J Renouf Janine M Davies Jonathan M Loree Sharlene Gill | 2020 | World Journal of Gastroenterology2020，26，39： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员